GLP1 usage is on the rise. This week on GameChangers, we discuss the latest data on using GLP-1s for sleep apnea and weight loss.

The GameChanger
Several new studies suggest GLP-1 and GLP/GIP medications have positive clinical impact on sleep apnea and weight loss.

Host
Jen Moulton, BSPharm
President, CEimpact

Guests
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Jake Galdo, PharmD, MBA, BCPS, BCGP
CEO
Seguridad

Reference
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the use of GLP-1 medications in the treatment of obstructive sleep apnea.
2. Discuss the relative weight loss in a recent study between a GLP-1 and GLP/GIP drugs.

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-238-H01-P
Initial release date: 07/29/2024
Expiration date: 07/29/2025
Additional CPE details can be found here.

The US is currently in the DSCSA stabilization period through November 27, 2024. Learn about the latest DSCSA details, including the most recent announcement from the FDA on exemptions from a leading DSCSA expert.

Host
Suzanne Feeney, PharmD
VP, Pharmacy Retail Operations
McKesson, Health Mart

Guests
Scott Mooney
VP, Distribution Operations
McKesson

References
Access the FDA Drug Supply Chain Security Act (DSCSA) website (https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa) to learn more about DSCSA.

Access the July 12, 2024 FDA Notification (https://www.fda.gov/media/179256/download?attachment) on DSCSA Exemptions from Certain Requirements Under Section 582 of the FD&C Act for Small Business Dispensers (revised with clarifying edits to June 12, 2024, letter).

Learn more about how pharmacies should prepare as the DSCSA stabilization Period Ends in this article (https://www.drugtopics.com/view/how-pharmacies-should-prepare-as-the-dscsa-stabilization-period-ends).


The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

1 out of 3 adult Americans take a daily multivitamin. On this episode of GameChangers, we discuss a recent study which examined whether daily multivitamin use extends life or prevents common causes of death.

The GameChanger
The study found no evidence that daily multivitamin use reduced death from common conditions such as heart disease or cancer.

Host
Jen Moulton, BSPharm
President, CEimpact

Guest
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Jake Galdo, PharmD, MBA, BCPS, BCGP
CEO, Seguridad

References
Multi-Vitamin Study
NIH Press Release

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the use of multivitamins.
2. Identify implications for healthy patients considering multivitamin use.

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-226-H01-P
Initial release date: 07/22/2024
Expiration date: 07/22/2025
Additional CPE details can be found here.